中国中西医结合杂志2017，Vol.37Issue(10)：1185-1190,6.DOI:10.7661/j.cjim.20170821.199
康氏抗纤方治疗慢性乙型肝炎肝纤维化的临床研究
Clinical Research of Kangshi Kangxian Recipe Treating on Hepatic Fibrosis of Chronic Hepatitis B
摘要
Abstract
Objective To observe the clinical effect of Kangshi Kangxian Decoction (KSKXD) in treating on patients of hepatic fibrosis of chronic hepatitis B (CHB),and to explore the mechanisms of KSKXD by regulating the contents of arachidonoylethanolamine (AEA),2-arachidonoylglycerol (2-AG),cannabinoid receptor 1 (CBR1 mRNA) and cannabinoid receptor 2 (CBR2 mRNA) in the liver tissue.Methods Totally 110 patients with hepatic fibrosis of CHB were assigned to the treatment group and the control group according to random digit table,55 cases in each group.The treatment group was treated with Chinese herb KSKXD combined with Entecavir,and the control group was treated with Entecavir.Both of the two groups were treated for 48 weeks.The clinical efficacy of the two groups was determined.The serum ALT levels,HBV DNA,HBsAg and HBsAb quantification,liver pathological changes,liver stiffness changes,contents of AEA and 2-AG,mRNA expression of CBR1 and CBR2 in the liver tissue were detected.Results The total effective rate,HBsAg negative conversion rate,hepatic fibrosis staging and curative effect rate of the treatment group were higher than those of the control group (x2 =4.453,4.152,6.364,all P ＜ 0.05).After treatment,the instantaneous elasticity of liver fibrosis,the contents of AEA and 2-AG,the mRNA expressions of CBR1 and CBR2 in the liver tissue in the two groups were decreased compared to those of the same group before treatment (P ＜0.05),and the treatment group had better effect than that of the control group (P ＜0.05).The pathological changes in the treatment group after treatment indicated the liver Iobules integrity,mild hydropic degeneration of liver cells,periportal fibrous tissue hyperplasia,local small lymphocytic infiltration,which fibrosis and inflammation were better than those of the control group.Conclusions KSKXD was effective in the treatment of hepatic fibrosis of CHB,which improved total effective rate,HBsAg seroconversion rate and liver fibrosis stage efficiency.And its mechanism maybe related to the regulation of the endocannabinoid system.关键词
康氏抗纤方/慢性乙型肝炎肝纤维化/内源性大麻素系统Key words
Kangshi Kangxian Decoction/hepatic fibrosis of chronic hepatitis B/endocannabinoid system引用本文复制引用
陈少东,张利敏,王瑶瑶,毛乾国,王宏国,庄鸿莉,蔡洋,罗晨,梁惠卿..康氏抗纤方治疗慢性乙型肝炎肝纤维化的临床研究[J].中国中西医结合杂志,2017,37(10):1185-1190,6.基金项目
国家自然科学基金资助项目(No.81503529,No.81673660) （No.81503529,No.81673660）
福建省科技计划引导性项目(No.2015D007,No.2016D012) （No.2015D007,No.2016D012）
厦门市科技惠民项目(No.3502220174028) （No.3502220174028）
福建中医药大学临床专项校管课题基金(No.XB2016080) （No.XB2016080）
